Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

Cell Cycle

Volumn 11, Issue 14, 2012, Pages 2756-2761

  Dean, Jeffry L ^a,b   McClendon, A Kathleen ^a,b   Hickey, Theresa E ^c   Butler, Lisa M ^c   Tilley, Wayne D ^c   Witkiewicz, Agnieszka K ^a,b   Knudsen, Erik S ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Breast cancer; Cell cycle; ER; Ex vivo; PD0332991

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MOLECULAR MARKER; RETINOBLASTOMA PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CANCER TISSUE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFICACY; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOPHYSIOLOGY; PRIMARY TUMOR; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

EID: 84864387137     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21195     Document Type: Article

References (20)

1. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-67; PMID:21633166; http://dx.doi.org/10.1172/JCI45014.
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52; PMID:10963602; http://dx.doi.org/10.1038/35021093.
3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-74; PMID:11553815; http://dx.doi.org/10.1073/pnas.191367098.
4. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 2010; 9:4153-63; PMID:20948315; http://dx.doi.org/10.4161/cc.9.20.13454.
5. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9:631-43; PMID:19701242; http://dx.doi.org/10.1038/nrc2713.
6. Johnston SR, Dowsett M, Smith IE. Towards a molecular basis for tamoxifen resistance in breast cancer. Ann Oncol 1992; 3:503-11; PMID:1498070.
7. Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, et al. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol 2011; 179:1171-8; PMID:21756866; http://dx.doi.org/10.1016/j.ajpath.2011.05.043.
8. De Palma M, Lewis CE. Cancer: Macrophages limit chemotherapy. Nature 2011; 472:303-4; PMID:21512566; http://dx.doi.org/10.1038/472303a.
9. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011; 25:2465-79; PMID:22156207; http://dx.doi.org/10.1101/ gad.180331.111.
10. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007; 7:659-72; PMID:17721431; http://dx.doi.org/10.1038/ nrc2193.
11. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11:R77; PMID:19874578; http://dx.doi.org/10.1186/bcr2419.
12. Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer 2011; 18:333-45; PMID:21367843; http://dx.doi.org/10.1530/ERC-10-0262.
13. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010; 29:4018-32; PMID:20473330; http://dx.doi.org/10.1038/onc.2010. 154.
14. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010; 29:4018-32; PMID:20473330; http://dx.doi.org/10.1038/onc.2010. 154.
15. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; 8:714-24; PMID:19143056; http://dx.doi.org/10.1038/nrc2401.
16. Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res 2010; 16:1094-9; PMID:20145169; http://dx.doi.org/10.1158/1078-0432. CCR-09-0787.
17. Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle 2011; 10:2497-503; PMID:21775818; http://dx.doi.org/10.4161/cc.10.15.16776.
18. van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, et al. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 2006; 6:86; PMID:16603054; http://dx.doi.org/10.1186/1471-2407-6-86.
19. Vaughn DJ, Flaherty K, Lal P, Gallagher M, O'Dwyer P, Wilner K, et al. Treatment of growing teratoma syndrome. N Engl J Med 2009; 360:423-4; PMID:19164198; http://dx.doi.org/10.1056/NEJMc0808558.
20. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28:2784-95; PMID:20404251; http://dx.doi.org/10.1200/JCO.2009.25.6529.